Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.

Langsjoen, Per H.; Vadhanavikit, Surasi; Folkers, Karl

doi:10.1073/pnas.82.12.4240

Cited by 119 publications

(60 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the first clinical trials of CoQ10 therapy in patients with HF was carried out in the 1980s (Langsjoen, et al, 1985). Langsjoen and colleagues (1985) demonstrated, in a study of 143 patients, an improvement in stroke volume and EF following CQ10 treatment over a 12-week period.…”

Section: Mitochondrial-targeted Antioxidantsmentioning

confidence: 99%

Cardiac metabolism — A promising therapeutic target for heart failure

Noordali

Loudon

Frenneaux

et al. 2018

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) are associated with high morbidity and mortality. Although many established pharmacological interventions exist for HFrEF, hospitalization and death rates remain high, and for those with HFpEF (approximately half of all heart failure patients), there are no effective therapies. Recently, the role of impaired cardiac energetic status in heart failure has gained increasing recognition with the identification of reduced capacity for both fatty acid and carbohydrate oxidation, impaired function of the electron transport chain, reduced capacity to transfer ATP to the cytosol, and inefficient utilization of the energy produced. These nodes in the genesis of cardiac energetic impairment provide potential therapeutic targets, and there is promising data from recent experimental and early-phase clinical studies evaluating modulators such as carnitine palmitoyltransferase 1 inhibitors, partial fatty acid oxidation inhibitors and mitochondrial-targeted antioxidants.Metabolic modulation may provide significant symptomatic and prognostic benefit for patients suffering from heart failure above and beyond guideline-directed therapy, but further clinical trials are needed.

show abstract

Section: Mitochondrial-targeted Antioxidantsmentioning

confidence: 99%

Cardiac metabolism — A promising therapeutic target for heart failure

Noordali

Loudon

Frenneaux

et al. 2018

Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…For adults 19 years & older; the recommended dose for Co Q10 supplementation is 30-200 mg daily. Studies have shown that supplementation with as little as 100 mg/dl for 12 months results in better pumping capacity, increased muscle strength & improved breathing [24].…”

Section: Coenzyme Q10 and Cvdmentioning

confidence: 99%

Impact of Intervention with Co-Enzyme Q10 on Homocysteine Levels of Cardiac Patients with Established Angiographic Evidence

Mathur¹

2014

JCTCD

View full text Add to dashboard Cite

Nutritionists and Health care professionals, epidemiologists and International agencies like WHO have been sounding an alarm on the remarkable increase in the incidence of Cardiovascular Diseases (CVD) for the past 15 years all around the world. It has been estimated that by 2020, CVD will be the largest cause of disability and death in India, which is the major reason why clinical research in this field is extremely relevant. The present study was undertaken to assess the nutritional status of twenty subjects suffering from coronary artery disease, cardiomyopathy, hypertension, mitral valve prolapse or coronary revascularisation with established angiographic evidence. Complete nutritional status assessment was done which included anthropometric, dietary and biochemical estimations. These subjects were then given 100 mg soft gel capsules of Coenzyme Q10 for a period of 60 days (this Intervention Trial was duly approved by the Institutional Ethics Committee). The study revealed that although the Body Mass Index (BMI) of the subjects was in the normal range they had high Waist/Hip Ratios indicating that central obesity was one of the risk factors for their CVD. The diets were found to be high in total fats and saturated fats, low in protein, fibre, and omega 3 fatty acids. The biochemical profile showed that the subjects had high levels of fasting and PP blood sugar and Lipoprotein A. homocysteine levels were found to be very high as compared to the normal values (p ≤ 0.01) in all the cardiac subjects prior to intervention. The subjects were asked to give their consent for the 60 days Intervention Trial with 100 mg of Coenzyme Q10 on Informed Consent Sheets. After Intervention all the Biochemical tests were conducted again. Results revealed that the impact of Coenzyme Q10 in lowering blood Sugar, Cholesterol, TG, LDL and Lipoprotein A levels was not significant which may be due to a modest dose and short intervention period of 60 days. homocysteine is a new emerging and independent risk factor for CVD There was a significant reduction (p ≤ 0.01) in the blood homocysteine (Hcy) levels of the subjects (from 22.52 ± 10.13 to17.08 ± 6.21). Hence in conclusion it can be said that Coenzyme Q10 is a rich, powerful and safe antioxidant with many beneficial therapeutic properties. Its supplements in the diet along with a diet which is rich in folic acid, both of which have a role in the correction of hyper homocysteinemia, can go a long way in the prevention of the global epidemic of CVD in the future times to come.

show abstract

“…Due to this function, CoQ 10 was developed as an ethical drug for heart failure in Japan in 1974. Thereafter, extensive clinical research on heart failure was conducted with CoQ 10 , and it was reported that oral supplementation (doses of 60 to 200 mg/day) of CoQ 10 improved various symptoms related to heart failure (Langsjoen et al, 1985;Morisco et al, 1993;Hofman-Bang et al, 1995).…”

Section: Introductionmentioning

confidence: 99%

Thirteen-Week Repeated Dose Oral Toxicity Study of Coenzyme Q10 in Rats

Honda¹,

Tominaga²,

Oshikata³

et al. 2007

J. Toxicol. Sci.

View full text Add to dashboard Cite

-As part of a safety evaluation of Coenzyme Q 10 , a subchronic toxicology study was conducted. Coenzyme Q 10 was repeatedly administered orally to male and female Crl:CD(SD) rats at daily dose levels of 300, 600 and 1200 mg/kg for 13 weeks. Neither death nor any toxicological signs were observed in any group during the administration period. No change related to the test substance administered was observed in any group with regard to body weight, food consumption, ophthalmoscopy, hematology, blood biochemistry, necropsy, organ weights or histopathology. Based on these results, the nonobserved-adverse-effect level (NOAEL) of Coenzyme Q 10 was considered to be 1200 mg/kg/day for male and female rats under these study conditions.

show abstract

Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.

Cited by 119 publications

References 4 publications

Cardiac metabolism — A promising therapeutic target for heart failure

Cardiac metabolism — A promising therapeutic target for heart failure

Impact of Intervention with Co-Enzyme Q10 on Homocysteine Levels of Cardiac Patients with Established Angiographic Evidence

Thirteen-Week Repeated Dose Oral Toxicity Study of Coenzyme Q10 in Rats

Contact Info

Product

Resources

About